LYSGF - Sio Gene Therapies: Excellent Data And News Obscured By Officer's Departure

• SIOX presented excellent data in its higher dose GM1 Gangliosidosis gene therapy program.
• Unfortunately, after hours that same day, its chief research and development officer announced he was moving on to another company.
• Investors seem to have latched on the latter news rather than the former which I think is short-sighted.
• I'm a buyer here with the company having plenty of cash, a miniscule EV and very promising clinical results.

For further details see: